Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Primary Purpose
Colon Cancer, Rectal Cancer
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MyChemoCare iPad application
Sponsored by
About this trial
This is an interventional supportive care trial for Colon Cancer
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with colon or rectal cancer
- Expected to live at least 6 months
- Initiating chemotherapy for the first time in their treatment history
- Physically and mentally able to participate
- Able to read English
- Willing and able to sign informed consent
Exclusion Criteria:
- A treatment plan that does not include cytotoxic chemotherapy for colon or rectal cancer
- A medical history that includes cancer with the exception of in situ cancers of the cervix and basal cell cancers of the skin
- A current diagnosis that includes multiple cancers (this does not exclude metastatic disease)
- Received prior cytotoxic chemotherapy for any reason
- A diagnosed psychiatric disorder
Sites / Locations
- University of Michigan
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MyChemoCare
Arm Description
Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
Outcomes
Primary Outcome Measures
Patient Retention and Engagement With the MyChemoCare Application
Patient retention is defined as the number of patients who completed the 8-week study through the final evaluation. Engagement with the MyChemoCare application was measured as number of patients who checked in at least once per week of the study.
Patient Satisfaction and Usability of the MyChemoCare Application
The investigators will use a 9-item survey developed by Dr. An to assess patients' experiences using the MyChemoCare app.
This result is the mean of the the survey items (with opposite items reversed). The scale was scored from 0 = Strongly disagree to 6 = Strongly agree.
Secondary Outcome Measures
Physician Use of the Study Feedback Mechanism
The investigators will assess for how many of the enrolled patients the physicians use the feedback from the app to assist in clinical care of the patients. This includes following up about distressing symptoms and using information provided by the patient during regular clinical visits.
Increased Mastery of Cancer and Chemotherapy Symptoms
The investigators will use the Cancer Care Mastery Scale to assess patients' feelings of control over their cancer care. This scale is based on the Mastery Scale developed by Pearlin and Schooler, designed to capture the sense of control a patient feels over their cancer care. This is a 7-item scale where users are asked to respond to statements by choosing and answer from the following: Strongly disagree, Disagree, Neither agree or disagree, Agree, Strongly agree. Mastery scores were computed by taking the numeric mean of the items (1-5), with negatively worded items reversed.
The number presented here is the number of patients whose mastery score improved between baseline and the end of the 8-week program. Because this is a small pilot study, we measure ANY improvement with no threshold specified.
Symptom Burden Reduction
The investigators will use the MD Anderson Symptom Inventory (MDASI) to describe patient experiences in 8 core symptom areas (pain, fatigue, nausea, disturbed sleep, distress, lack of appetite, weakness, and diarrhea). For each area, patients are asked to rank their symptoms on a scale from 0 (Not present) to 10 (As bad as you can imagine). The overall score is the mean across all 8 items.
The number reported here is the count of patients with a reduction in symptom burden between baseline and 8-week follow up. Because this is a small pilot study, we measure ANY reduction with no threshold specified.
Improved Quality of Life
The investigators will use the FACT-G survey to assess four dimensions of patients health (physical, functional, social and emotional). For each of the dimensions, patients are given a series of statements about specific elements of well being and asked to rank them on the following scale: Not at all, a little bit, Somewhat, Quite a bit, or Very much. These items are given numeric values of 0-4, with negatively worded statements reverse coded. Within each of the four dimensions of health, average scores are calculated, and then an overall sum is derived. Total well-being ranges from 0 (Complete lack of well being) to 16 (Completely well).
The number presented is the count of participants for whom the overall FACT-G score increased between baseline and 8-week followup. Because this is a small pilot study, we measure ANY increase with no threshold specified.
Full Information
NCT ID
NCT02460822
First Posted
October 22, 2014
Last Updated
March 29, 2017
Sponsor
University of Michigan
Collaborators
McKesson Foundation
1. Study Identification
Unique Protocol Identification Number
NCT02460822
Brief Title
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Official Title
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
October 2014 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Michigan
Collaborators
McKesson Foundation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research project addresses critical gaps in cancer symptom management through the creation of a mobile chemotherapy symptom management application. This application will assess for the presence and severity of common chemotherapy side-effects and provide personally tailored symptom-related video and narratives to enhance self-management of cancer and treatment-related symptoms. This study will examine patient acceptance and use of this mHealth application (called MyChemoCare) in a prospective trial of cancer patients (n=60) who are receiving chemotherapy for colorectal cancer at the University of Michigan Comprehensive Cancer Center.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colon Cancer, Rectal Cancer
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
MyChemoCare
Arm Type
Experimental
Arm Description
Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
Intervention Type
Device
Intervention Name(s)
MyChemoCare iPad application
Primary Outcome Measure Information:
Title
Patient Retention and Engagement With the MyChemoCare Application
Description
Patient retention is defined as the number of patients who completed the 8-week study through the final evaluation. Engagement with the MyChemoCare application was measured as number of patients who checked in at least once per week of the study.
Time Frame
8 weeks post-enrollment
Title
Patient Satisfaction and Usability of the MyChemoCare Application
Description
The investigators will use a 9-item survey developed by Dr. An to assess patients' experiences using the MyChemoCare app.
This result is the mean of the the survey items (with opposite items reversed). The scale was scored from 0 = Strongly disagree to 6 = Strongly agree.
Time Frame
8 weeks post enrollment
Secondary Outcome Measure Information:
Title
Physician Use of the Study Feedback Mechanism
Description
The investigators will assess for how many of the enrolled patients the physicians use the feedback from the app to assist in clinical care of the patients. This includes following up about distressing symptoms and using information provided by the patient during regular clinical visits.
Time Frame
8 weeks post-enrollment
Title
Increased Mastery of Cancer and Chemotherapy Symptoms
Description
The investigators will use the Cancer Care Mastery Scale to assess patients' feelings of control over their cancer care. This scale is based on the Mastery Scale developed by Pearlin and Schooler, designed to capture the sense of control a patient feels over their cancer care. This is a 7-item scale where users are asked to respond to statements by choosing and answer from the following: Strongly disagree, Disagree, Neither agree or disagree, Agree, Strongly agree. Mastery scores were computed by taking the numeric mean of the items (1-5), with negatively worded items reversed.
The number presented here is the number of patients whose mastery score improved between baseline and the end of the 8-week program. Because this is a small pilot study, we measure ANY improvement with no threshold specified.
Time Frame
8 weeks post enrollment
Title
Symptom Burden Reduction
Description
The investigators will use the MD Anderson Symptom Inventory (MDASI) to describe patient experiences in 8 core symptom areas (pain, fatigue, nausea, disturbed sleep, distress, lack of appetite, weakness, and diarrhea). For each area, patients are asked to rank their symptoms on a scale from 0 (Not present) to 10 (As bad as you can imagine). The overall score is the mean across all 8 items.
The number reported here is the count of patients with a reduction in symptom burden between baseline and 8-week follow up. Because this is a small pilot study, we measure ANY reduction with no threshold specified.
Time Frame
8 weeks post enrollment
Title
Improved Quality of Life
Description
The investigators will use the FACT-G survey to assess four dimensions of patients health (physical, functional, social and emotional). For each of the dimensions, patients are given a series of statements about specific elements of well being and asked to rank them on the following scale: Not at all, a little bit, Somewhat, Quite a bit, or Very much. These items are given numeric values of 0-4, with negatively worded statements reverse coded. Within each of the four dimensions of health, average scores are calculated, and then an overall sum is derived. Total well-being ranges from 0 (Complete lack of well being) to 16 (Completely well).
The number presented is the count of participants for whom the overall FACT-G score increased between baseline and 8-week followup. Because this is a small pilot study, we measure ANY increase with no threshold specified.
Time Frame
Baseline and 8 weeks post enrollment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with colon or rectal cancer
Expected to live at least 6 months
Initiating chemotherapy for the first time in their treatment history
Physically and mentally able to participate
Able to read English
Willing and able to sign informed consent
Exclusion Criteria:
A treatment plan that does not include cytotoxic chemotherapy for colon or rectal cancer
A medical history that includes cancer with the exception of in situ cancers of the cervix and basal cell cancers of the skin
A current diagnosis that includes multiple cancers (this does not exclude metastatic disease)
Received prior cytotoxic chemotherapy for any reason
A diagnosed psychiatric disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Larry C An, MD
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management
We'll reach out to this number within 24 hrs